Edition:
India

Prometic reports positive interim clinical data from IVIG phase 3 trial


Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Prometic Life Sciences Inc :Prometic reports positive interim clinical data from ongoing intravenous immunoglobulin (IVIG) pivotal phase 3 trial.Prometic Life Sciences Inc - ‍interim clinical data shows non inferiority to commercially-approved products for primary immunodeficiencies​.Prometic Life Sciences - ‍clinical data confirmed no significant safety issues, efficacy appeared to be comparable to existing commercial IVIG products​. 

Company Quote

13.6
0.03 +0.22%
4 Oct 2019